CLOs on the Move

Behavioral Medical Research of Staten Island, PC

www.bmrsi.com

 
Behavioral Medical Research of Staten Island, PC is a Staten Island, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Windy City Cannabis

Windy City Cannabis is your Chicagoland dispensary. Visit our medical and recreational dispensary locations near you in Homewood, Justice, Posen and Worth.

SpineWorks Medical

SpineWorks Medical is a Huntington Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Redemption Cannabis

#RedemptionCanna

Cleveland Biolabs

Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We have additional pipeline product candidates in various stages of development.

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.